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SUMMARY
The results of experiments in an animal model for 
obesity, namely obese hyperglycaemic mice (ob/ob) are 
described and their relevance to the study of obesity 
and endogenous hyperlipaemia in man is discussed.
Alternating periods of fasting and refeeding reduced 
the body weight, blood glucose, and plasma insulin levels 
of obese hyperglycaemic (ob/ob) mice, which also showed 
an increase in physical activity. A return to normal 
feeding habit reversed these changes. ob/ob mice showed 
no weight loss when treated with various doses of tri­
iodothyronine (T^), 'slim' ob/ob mice did not breed, and 
an unexpected number of lipomas at the tail .of the pancreas 
was discovered in these animals.
A study of changes in the distribution and numbers 
of gut hormone-producing cells in these mice was commenced 
and the possibility that these 'insulin-releasing' gastro­
intestinal hormones may be involved in the development of 
obesity is discussed.
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NON-STANDARD ABBREVIATIONS
bw Body weight
Ci Curie
EDTA Ethylene diamine tetracetic acid
EGTA Ethylene glyccl-bis-(0 -aminoethylather)
IP Intraperitoneal
IRG Immuno reactive glucagon
IRI Immuno reactive insulin
IRP Intestinal insulin-releasing polypeptide
IU International units
IV Intravenous
MEM Minimum essential medium
MLD Minimum lethal dose
PAS Periodic acid schiff
PBS*A* Phosphate buffered saline lacking calcium and
magnesium 
PCA Perchloric acid
RIA Radioimmunoassay
SC Subcutaneous
SEM Standard error of the mean
Tg Triiodothyronine
TPB Tryptose phosphate broth
U Unit
VIP Vasoactive intestinal polypeptide
HE
FFA
GLI
GIP
N,N-tetra acetic acid 
Free fatty acids 
Gastric inhibitory polypeptide 
Glucagon-like immunoreactivity 
Haematoxy1in and eosin
Other abbreviations are those recommended by the 
*Biochemical Journal* chemical formulae are those •
m  common use
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C H A P T E R  1
GENERAL INTRODUCTION
Obesity which may be defined as an excess of body fat, 
is the most important nutritional disease in the affluent 
countries of the world (Kannel, LeBauer, Dawber and McNamara 
1967; Baird 1973; Mann 1975). A survey in the United 
States showed that about two thirds of the population is 
overweight to the extent associated with diminished life 
expectancy (Office of Health Economics 1969).
In the Framingham Heart Disease and Epidemiology Study, 
obesity was the factor most closely associated with the 
frequency of athersclerotic cardiovascular disease and was a 
determinant of the risk factors for hypertension, hyperlipaemia 
and diabetes (Kannel et al 1967? Gordon and Kannel 1973; 
Pfeiffer and Laube 1974; Clark and Duncan 1972; Walker 1972).
The association of obesity with many disabling but non- 
fatal diseases is also well documented; for example, osteo­
arthritis of the knee is common in middle-aged obese women 
(Leach, Baumgard and Broom 1973). V
There is known to be a genetic component in the 
causation of obesity, but it has been difficult to separate 
this genetic effect from the contribution made by 
environmental factors. Genetic factors appear to have a 
greater influence on the extent of fat deposition in the 
trunk than in the limbs (Brook, Huntley and Slack 1975).
Weight reduction of moderately obese men, on a weight- 
reducing diet, resulted in a marked fall in their plasma 
cholesterol and triglyceride levels (Leelarthaepin, Woodhill, 
Palmer and Blacket 1974). It was therefore suggested that both 
body weight and the composition of the diet are important 
determinants of plasma lipid levels. Weight gain after 
maturity makes an important contribution to Type II and IV 
hyper lipaemia. . J,
Weight reduction improves life expectancy, is often the 
most useful step in treating osteoarthritis of the knee and may 
prevent other disorders associated with obesity (Dublin 1953) .
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Many methods to reduce the weight of obese subjects 
have been tried with various degrees of success (Garrow 1974). 
Substantial weight reduction is often very difficult to 
achieve - indeed some authorities despair of the efficacy of 
many forms of dietary advice for making people lose weight 
permanently (Stunkard 1972; Garrow 1974; Lancet Editorial
1974). Anorectic drugs are of limited usefulness in the 
treatment of obesity. Drug treatment never seems to achieve 
weight-loss greater than 20 kg-average-(Duncan and Munro 1968; 
Steel, Munro and Duncan 1973; Blundell 1974).
In the face of these disheartening results, more and 
more drastic treatments for gross obesity have been tried. 
Despite the unpleasant side-effects, Jejunal and Ileal - bypass 
surgery are gaining ground as a line of treatment in severe 
obesity (Baddeley 1973; Bliss 1973; Gazet, Pilkington,
Kalucy, Crisp and Day 1974; Clinical Nutrition Editorial
1975). \
Since treatment is so difficult, attention has 
increasingly been directed towards prevention, although we 
still lack satisfactory methods for the prevention of obesity 
(Garrow 1974).
In the last 25 years, there has been extensive research 
into obesity and hyperlipaemia, both in man and in experimental 
animals. Despite all the efforts, however, the mechanisms 
which are ultimately responsible for obesity and hyperlipaemia 
remain unknown (Albrink 1974; Bray and York 1971; Bruch, 1974; 
Galton 1971; Garrow 1974; Gordon 1970; Howard 1975;
Jequier 1975; .Mahler 1974; Rabinowitz 1970; Schachter and 
Rodin 1974; Scheig 1974; Vague 1969; Vague and Boyer 1974;
Welsh 1962; Whelan and Silverstone 1974).
The role of>various hormones in producing and/or •• 
maintaining the obese state and hyperlipaemia has not been 
resolved. Insulin and glucagon, two hormones, which influence 
carbohydrate and lipid metabolism, have been implicated in 
the pathogenesis of obesity and hyperlipaemia (Marks and
Samols 1968; Marks 1973; Schade and Eaton 1974).
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Attempts to find correlations between hyperinsulinaemia, 
hypertriglyceridaemia (frequently associated with obesity) and 
obesity have not yielded consistant results (Bernstein, Grant 
and Kipnis 1975; Leelarthaepin et al 1974; Tremolieres, 
Sautier, Carre, Fiament and Plumas 1974). Hyperinsulinaemia 
was thought by some workers to be due to a primary 3-cell 
abnormality.
A mechanism has been recently postulated for both 
genetic and acquired endogenous hyperlipaemias seen in man 
and in experimental animals (Eaton and Schade 1973; Eaton, 
Schade and Conway 1974). It is suggested that the 
hypolipaemic action of glucagon, which is less marked in 
various hyperlipaemic states (for example, dietary, cobalt 
inducing, or genetic hyperlipaemia) might be responsible for 
the development and/or the maintenance of endogenous 
hyper1ipaemia.
The evidence for the possible role of some of the gut 
hormones in the regulation of insulin secretion, reviewed 
recently by Grossman and his colleagues (1975), has opened 
up a new era in the search for the primary defect responsible 
for obesity and associated disorders such as hyperlipaemia 
and diabetes.
Ethical and practical difficulties are encountered 
with experiments on human subjects. Therefore, there is a 
great need for experimental animal models with features 
resembling those found in human obesity, hyperglycaemia and 
hyperlipaemia, for use in the study of these states and 
influencing factors.
Obese hyperglycaemic mice (ob/ob) and rats with 
cobalt chloride induced hyperlipaemia, have been used as 
experimental models in the present study.
- 10 -
C H A P T E R  2
MATERIALS AND METHODS
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A. Materials
I - Animals
Obese Hyperglycaemic Mice (ob/ob)
Mice, homozygous for the obese gene and bred from 
a mixed strain into which the ob gene had been incorporated 
(Abraham, Dade, Elliott, and Hems, 1971) were used together 
with their lean littermates (Fig.2:1). Animals were aged 
4-6 months at the beginning of the studies described in the 
following Chapters and were bred in the University of Surrey 
Animal Unit.
II - Chemicals
Routine chemicals - Analar grade - were obtained 
from BDH, Poole; other chemicals, radiochemicals and media 
were supplied by various companies which are listed in 
Appendix I.
Fig. 2:1
An obese hyperglycaemic mouse and its lean 
littermate aged 6 months.
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B. Methods
1. Measurement of Radioactivity by Liquid Scintillation Countin
All radioactivity measurements were made using a Packard 
Tri Carb Liquid Scintillation Counter, Model 3320. The 
scintillation mixture contained PPO (0.4%) and POPOP (0.1%) in 
toluene/Triton X-100; 2:1 (vol/vol).
For counting, 20 yl of medium perfusate or diluted bile 
was 'pipetted into scintillation vials containing 6 ml 
scintillant. The vials were shaken and counted for 10 minutes.
The counting efficiency in case of lifC was about 80% 
and for 3H about 42%.
2. The Measurement of Glucose and Insulin Levels
Samples for glucose measurements including blood were 
collected into 0.05 ml capillary pipettes and discharged into
0.95 ml 2% . perchloric acid (PCA) . The tubes were then
centrifuged and kept at 4°C until measurement.
Glucose was measured in the Auto-analyser (Technicon Ltd.) 
using an automated GOD-perid method (Catalogue no. 15703, 
supplied by Boehringer Manheim Ltd.). This method uses the 
chromagen ABTS (ammonium salt of 2,2’ azino-di (3-ethyl-benzo- 
thiazoline-6-sulphonic acid)) as redox indicator, with 
glucose oxidase and peroxidase (Kahle et al 1970).
Samples, for insulin assay, including plasma, were 
collected into heparinised micro-centrifuge tubes (Gelman- 
Hawksely) and -kept on ice until centrifuged. After 
centrifugation at 2,000 r.p.m. for 15 minutes the tubes were 
stored upright at.-20°C until analysis. The portion;of the 
tube which contained plasma was cut off just prior to 
determination.
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Insulin levels were measured by a double antibody 
radioimmunoassay procedure, described in detail by 
Shabaan (M.Sc. Thesis 1973).
3. Measurement of Plasma Lipids
Fresh, unhaemolysed, serum was used to measure some 
of the plasma lipid constituents, i.e. triglyceride, 
cholesterol and free fatty acids (FFA).
Serum triglyceride levels were determined colori- 
metrically according to the method described by Fletcher 
(1968). This method was based on the principle that the 
glycerol released by saponification of the serum glycerides 
is oxidized to formaldehyde which reacts with acetylacetone 
to form a yellowT dihydrolutidine derivative absorbing at 
405 nm.
Cholesterol was measured colorimetrically following 
addition of acetic anhydride and concentrated sulphuric 
acid. The procedure and the reagents were supplied by 
Boehringer Manheim, London (Cat.No. 15969).
Serum FFA levels were also measured colorimetrically 
using a commercial kit (Boehringer Manheim (Cat.No. 15989)).
RQuality control sera, Liponome , (BDH, Poole) and 
RSeronorm (Nyegard-Norway), were used with all batches.
Other analytical techniques and methods which include 
autoradiography, atomic absorption spectroscopy and 
histological techniques, were also used. These techniques 
are described in appropriate sections in this Thesis.
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C H A P T E R 3
INVESTIGATIONS ON OBESITY
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Chapter 3; Contents
Introduction
The reduction of body weight in obese
hyperglycaemic mice (ob/ob)
(1) Reduction of body weight, plasma insulin 
and blood glucose levels, by alternate 
fasting and refeeding regime in obese 
hyperglycaemic mice (ob/ob)
(2) The effect of triiodothyronine (Tg) 
treatment on body weight
(3) Breeding from obese mice (ob/ob) after 
weight reduction ,
Lipomas in obese hyperglycaemic mice (ob/ob)
1 - lipomas in obese mice following weight
reduction
2 - discussion
The possible role of gut hormones in the
development of obese hyperglycaemic mice
(ob/ob)
Discussion
3.1: Introduction
The recessively inherited obese-hyperglycaemic syndrome 
in mice was first described in 1950 by Ingalls, Dickie and 
Snell. All mice homozygous for the gene (ob/ob) manifest 
the syndrome of which the most distinguishing feature is an 
excessive and abnormal deposition of fat (Mayer, Dickie, Bates 
and Vitale 1951).
In addition to the increased body weight these mice are 
characterised by insulin resistant hyperglycaemia (Mayer, 
Russell, Bates and Dickie 1953; Mayer 1953; Shull and Mayer 
1956), together with high levels of circulating insulin 
(Stauffacher, Lambert, Vecchio and Renold 1967) altered fat 
metabolism (Heilman, Larsson and Westman 1962; Mayer and 
Jones 1953) and greatly enlarged functionally hyperactive 
islets of Langerhans, of which about 90% are 3-cells (Gepts, 
Christophe andMayer 1960; Heilman, Brolin and Hellerstrom 
1961; Heilman and Peterson 1960).
Other endocrine abnormalities are recorded in the ob/ob 
mice; Naeser (1974) showed that ob/ob had elevated plasma 
corticosteroids compared with their lean controls. Edwardson 
and Hugh (1975) showed that they have adrenal hypertrophy, 
increased corticosteroid secretion and considerably increased 
levels of pituitary ACTH.
Cycling periods in female obese mice (ob/ob) is either 
irregular or infrequent, however, the ova of ob/ob mice are 
fertile (Coleman and Hummel 1968).
Male obese mice (ob/ob) have considerably reduced 
volume and nuclear size of Leydig cells (Heilman, Jacobsen 
and Taljedal 1963; Lidell and Heilman 1966). A return of 
fertility to ob/ob mice of restricted body weight was 
reported by Lane and Dickie (1954).
Conflicting evidence about the role of thyroid in the 
development of obese-hyperglycaemic syndrome in ob/ob mice 
were reported.
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No abnormalities either in thyroid weight or 
histology, have been detected in ob/ob mice (Bray and York 
1971). The thyroid status of the ob/ob mouse, as measured 
by the uptake of 131I, was shown to be normal (Goldberg and 
Mayer 1952; Wykes, Christian and Andrews 1958). However, 
this was recently challenged by Joosten and Van Der Kroon (1974) 
who suggested that ob/ob moucse is hypothyroid.
Thyroid function in the obese human subjects, as 
measured by radio-iodine thyroid uptake showed some differences 
from normal weight controls. The dynamic thyroid tests seem 
to indicate that the * lazy thyroid* is due to a functional 
impairment in the control of the hypothalamus and/or pituitary 
(Riviere, Roger, Nogue, Emperaire and Latapie 1975).
Bray, Melvin and Chopra (1973) reported small decrease 
in the body weight of six grossly obese subjects, as a result 
of treatment with triiodothyronine (T^ ) . •
Bray and York (1971) suggested that a hypothalamic defect 
might be involved in expression of the genetic abnormalities 
in ob/ob mice. Belloff-Chain, Edwardson and Hawthorn (1975), 
show that the insulin-releasing effect is not produced by 
ACTH, GH or prolactin in ob/ob mice, but possibly by a pituitary 
insulin-releasing factor which might be corticotrophin-like 
intermediate lobe peptide (CLIP) - (Edwardson 1975 - personal 
communication). This polypeptide was isolated and identified 
in the pig by A. Scott and his colleagues (Scott, Lowry, 
Ratcliffe, Rees and Landon 1974; Scott, Lowry, Bennett, 
McMartin, Ratcliffe 1974).
Roos, Martin, Westman-Naeser and Hellerstrom (1974), .. 
measured immunoreactive growth hormones levels in ob/ob mice 
and lean controls. They concluded that the insulin resistance 
of obese-hyperglycaemic animals was unlikely to be caused by 
pituitary hypersecretion of growth hormone.
Obese mouse (ob/ob) was also found to be characterised 
by a decrement in the concentration of insulin receptors per 
cell. Insulin receptors in liver, fat and thymic lymphocytes
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are similarly affected, and in the lymphocytes, a decrease in 
receptor concentration is associated with a loss in insulin- 
stimulated amino iso-butyric acid transport. Total fasting 
for 24 hours or restriction of food intake to normal levels 
for a period of weeks, elevated insulin binding to normal or 
near normal levels (Freychet, Laudat, Lauaat, Rossein Kahn, 
Gorden and Roth 1972; Kahn, Neville, Gorden, Freychet and 
Roth 1972; Kahn, Neville and Roth 1973; Soli, Goldfine,
Roth and Kahn 1974).
It is now well recognised that intestinal hormones 
are concerned in the regulation of glucose homeostasis 
(McIntyre, Holdsworth and Turner 1965; Marks and Samols 
1970) but their absolute identity and relative importance are 
uncertain (Pearse 1974; Grossman et al 1975).
Two recently isolated polypeptides, intestinal insulin 
releasing polypeptide (IRP) (Turner and Marks 1972; Turner, 
Shabaan, Etheridge and Marks 1973; Shabaan ,1973; Shabaan, 
Turner and Marks 1974 a, b) and gastric inhibitory polypeptide 
(GIP) (Brown, Mutt and Pederson 1970; Brown,. Pederson, Jorpes 
and Mutt 1969) were shown to produce dramatic effects on serum 
insulin levels in response to intravenous glucose in the rat 
(Dupre, Ross, Watson and Brown 1973; Rabinovitch and Dupre 
1974; Turner, Etheridge, Marks, Brown and Mutt 1974) and in 
baboon (Turner, Etheridge, Jones, Marks, Meldrum, Bloom and 
Brown 1974).
Since the hormones of the gastrointestinal tract may 
play a part in the regulation of blood glucose levels through 
the release of pancreatic hormones, estimation of number and 
distribution of gut hormone-producing cells in ob/ob mice 
(Polak, Pearse, Grimelius and Marks 1975) was the first direct 
evidence of a possible role of gut hormones in the development 
of obese hyperglycaemic syndrome in ob/ob mice. They showed 
a degree of hyperplasia of most of the endocrine (APUD) cells 
(apudosis) in all regions of the gastrointestinal tract in 
ob/ob mice. In addition they also showed a significant 
difference in both number and hormone content of GIP, and
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enteroglucagon (gut glucagon cross-reacting material, 
glucagon-like immunoreactivity, GLI) cells (P <0.001) 
in obese mice as compared to lean mice. Differences in 
the case of secretin, gastrin, vasoactive intestinal poly­
peptide (VIP) cells were not great in the obese mice, but 
in the obese mice both gastrin and secretin cells were 
present in larger numbers in the lower intestine, whereas 
in the lean mice they were predominant in the upper 
intestine.
Despite all the information available, however, the 
mechanism ultimately responsible for the obese hyperglycaemic 
syndrome remains unknown.
Many of the current methods, used for body weight 
reduction in obese human subjects, are not satisfactory 
(Mann 1975). This is because they either fail to produce 
marked weight reduction in many patients (as,in the low 
carbohydrate diets) or they are too hard to be tolerated by 
the majority of obese subjects (as in the complete food 
intake restriction for long periods).
A possible new approach to the problem of body weight 
reduction was tested in obese hyperglycaemic mice (ob/ob) 
using alternate, periods of fasting and refeeding.
The following studies were carried out:
1. Measurement of body weight reduction in ob/ob mice 
using alternate periods of fasting and refeeding.
2. The effect of body weight reduction on blood glucose, 
plasma insulin, physical activity and possible 
breeding from * slim' ob/ob mice..
3. The effect of triiodothyronine on body weight of 
ob/ob mice.
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4. The effect of body weight and plasma insulin reduction
on numbers and distribution of gut hormone-producing 
cells in ob/ob mice; in order to establish whether the 
obesity is due to hyperinsulinaemia or another primary 
abnormality causing both manifestation.
- 24
.2 The Reduction of Body Weight in
Obese Hyperglycaemic Mice (ob/ob)
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(1) Reduction of body weight, plasma insulin and blood glucose
levels, by alternate fasting and refeeding regimes in obese 
hyperglycaemic mice (ob/ob)
Obese hyperglycaemic mice (ob/ob) aged 5-6 months at the 
beginning of the studies, had been fed on normal rat chow diet 
and water ad libitum.
Blood for glucose and insulin measurement was obtained 
either from the tail vein or by heart puncture at the 
conclusion of the experiments.
Physical activity was measured simultaneously in an 
experimental animal and its control using two activity wheels 
(tread wheels) connected by microswitches to a single channel 
recorder (Servoscribe-Venture). Rotation of either of the two 
activity wheels was received as a pulse by the recorder and 
registered as a deviation from the midline on the same side of 
the recorder as the activated wheel (Fig.3.2:1). The micro­
switches on the activity wheels operated regardless of the 
direction of rotation.
The activities of the test mouse and its control were 
compared for 60 minutes and expressed as oscillation per hour.
(a) 72 hours fasting, 24 hours 'ad libitum1 feeding regime
Two groups of six obese mice of the same age group (5-6 
months) were weighed at the beginning of the study (Fig.3.2:2). 
Food was withheld from the test group for 72 hours followed by 
a 24-hour period during which access to food was allowed ad 
libitum. This cycle of fasting and refeeding was repeated 
during seven weeks (Fig. 3. 2:3-4) . Water was freely available 
at all times. At the end of seven weeks normal feeding was 
resumed. After four weeks the animals were sacrificed. The 
control group was maintained on normal feeding throughout the 
eleven-week period.
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Fig. 3.2:1 Apparatus used to measure the physical 
activitv.
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-Fig. 3.2:2 Three out of the six test obese hypergly­
caemic mice at the beginning of a weight 
reduction regime (72 hours fasting, 24 hours 
ad libitum feeding).
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Fig. 3.2:3 Three out of the six test obese hyper­
glycaemic mice after se"ren weeks of a 
72 hours fasting, 24 hours ad libitum 
feeding regime.
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Fig. 3.2:4 An obese mouse (right) after seven weeks
on a 72 hours fasting, z 4 hours ad libitum 
feeding regime, its lean littermate and its 
obese control, fed ad_ 3 lbiturn throughout the 
seven weeks experimental period, are shown . 
for comparison.
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Body weight was recorded weekly for both groups; in 
the test group measurements were made at the end of the feeding 
day. The results are shown in Fig. 3.2:5.
Weight loss was more or less constant throughout the 
period of fasting and refeeding, and averaged 6% per week, 
totalling 41% at the end of seven weeks. On resumption of 
normal feeding during the 8th-llth week the rate of weight 
gain averaged 9% per week.
A similar experiment was performed using twenty younger 
obese mice, aged four months (they did not reach their 
maximum weight).
The average weights (g) during this experiment are shown 
in Table 3.2:1.
. Weeks
i
0 7 11
Obese controls (10) 95 97 97
Obese test (10) .91 47 94
Table 3.2:1
During this experiment two of the obese controls died towards 
the end of the experiment, whereas none of the test mice died 
during the period of the experiment.
(b) 48 hours fasting, 24 hours 'ad libitum1 feeding regime
In this experiment the animals (five mice in each group) 
were treated in the same manner as above except that the 
fasting period was reduced to 48 hours (Fig. 3.2:6). Physical
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Fig. 3.2:5 Body weight ( M± SEM ) of test animals during seven 
weeks of 72 hours fasting/24 hours ad libitum feeding 
regime, followed by four weeks normal feeding. 
Normal weight of the control group also shown.
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Fig. 3.2:6 Control obese mouse fed ad libitum (left), 
and its obese littermate after seven weeks 
of 48 hours fasting, 24 hours feeding regime 
(right).
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activity, body weight, overnight fasting, blood glucose and 
plasma insulin levels were measured at various times 
throughout the experiment and the results are shown in 
Fig. 3.2:7. Changes in body weight correlated well with 
changes in blood glucose (correlation coefficient ; f == 0.992; 
p <0.001) and changes in plasma insulin levels (correlation 
coefficient T- 0.993; p <0.001). Physical activity in the 
test animals increased as their body weight decreased but had 
fallen again to basal values by the end of the experiment by 
which time body weight had returned to its initial level.
(2) The effect of triiodothyronine (T^) treatment on body weight
Five obese mice and two lean littermates (aged 5-6 months) 
received a daily oral dose of T^, dissolved in the drinking 
water. The dose was calculated from a knowledge of the animals 
average water intake and was initially given at a dose of 
0.5 yg/kg body weight for three weeks and finally to 2 yg/kg 
for the rest of the eleven-week period. A bontrol group of 
four obese mice did not receive any T^.
The results are shown in Fig. 3.2:8 and indicate that 
despite the relatively high dose of T^ used in these 
experiments there was no significant weight change in either 
the obese or lean treated mice.
(3) Breeding from obese mice (ob/lb) after weight reduction
Six young obese hyperglycaemic mice (ob/ob) - (three
males and three females), aged ten weeks and weighed 66 g 
(mean), at the beginning of this study. The animal then 
underwent an initial period of four weeks of weight reduction, 
by a 48 hours fasting, 24 hour ad libitum feeding regime.
At the end "of this period each 'slim* obese mouse (mean
weight 37 g) was joined in a separate cage, with an opposite 
sex lean control mouse, of proven fertility (average weight 
32 g). The pairs of mice were kept on normal feeding ad 
libitum for weight weeks, followed by another period (eight 
weeks) of alternate fasting and feeding as before.
- 34 -
Bl
oo
d 
G
lu
co
se
 
m
g/
lO
O
m
l 
Bo
dy
 
W
ei
gh
t 
g.
Changes in physical activity, weight, glucose, and insulin in ob-ob 
mice on 4b hours fasting/24 hours_ad libitum feeding regim e.
r-240
-220
-200Fasting or refeeding. Normal ieeding
1 2 0 -
1 0 0 -
80 ~ c
- 2 0Activity
180
Glucose
-120160 -i
100 p
120
Insulirv
100 -i
Weeks
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activity (a — a ) blood glucose (a— a ) and plasm a insulin  
(0 =7=0 ) levels in obese mice during seven weeks of 48 hours 
fasting/24 hours ad libitum feeding regim e, followed by 
4 weeks normal feeding.
Histograms show activity, blood glucose and plasm a insulin  
ipvp.ls.in obese controls and lean letterm ates.
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Fig; 3 .2:8  Effect of 3 doses of tri-iodothyronine ( T3 ) upon body 
weight ( Mean ± SEM ).
x—x obese mice (10), o — o lean lettermates (2),®— ® 
obese mice not receiving T3 (10).
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During the whole experimental period, no mating was 
observed between any pair, and none cf the animals (lean or 
ex-obese females) became pregnant despite the fact that the 
weight of 'slim* obese mice was similar to that of the lean 
control mice.
DISCUSSION
The present study clearly shows that both the alternate 
fasting and refeeding regimes used are capable of producing 
marked reduction in body weight in obese mice (ob/ob) within a 
relatively short period (seven weeks).
The data suggests that weight loss was due mainly to a 
decrease in food intake rather than to the increase in 
physical activity. Since all the measurements of physical 
activity were carried out on the feeding day it is unlikely 
that food-seeking was an important factor in the increased 
activity observed.
Blood glucose and plasma insulin levels followed the 
pattern of weight change and the direct and close correlation 
between the various parameters was striking. By contrast, 
physical activity was inversely correlated with body weight, 
plasma insulin and blood glucose levels.
The rapid increase in overnight fasting blood glucose 
and plasma insulin during normal feeding (8-11 weeks) suggests 
that both are secondary manifestations of a prime cause 
(hyperphagia), which is responsible for the obese hyperglycaemic 
syndrome, rather than primary abnormalities. This point will 
be further discussed in Section 3.5.
Treatment with varying doses of triiodothyronine (Tg) 
failed to cause significant weight loss in obese mice (ob/ob) 
which had free access to food. It was therefore decided not 
to measure TSH, T^, T^ levels in the blood of these mice, as 
was originally planned.
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The suggestion by Joosten and Van Der Kroom (1974) 
that the obesity of the ob/ob mice is due to hypothyroidism 
received no support from the present work which does not, 
however, preclude the possible involvement of other hormonal 
factor.
Breeding from obese mice tfemales and males) which 
underwent weight reduction regime, was not possible. This 
suggests that the infertility in ob/ob mice is not due to 
obesity as such, but to another primary abnormality.
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3.3 Lipomas In Obese Hyperglycaemic Mice (ob/ob)
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1 - Lipomas in Obese Mice Following Weight Reduction:
Whilst dissecting obese and lean control mice in 
preparation for histological and immunocytochemical experiments 
(see Section 3.4), a striking number of masses (lipomas) were 
found in some of the 'slim* obese mice which have been on a 
72 hours (three days) fasting, 24 hours (one day) ad libitum 
feeding regime, for seven weeks (Fig.3.3:1).
Six out of twelve of the test mice had lipomas, all 
attached to the tail of the pancreas (Fig. 3.3:2-7). No 
lipomas were found in the twelve obese controls, nor the 
twelve lean control mice from the same experiment and 
dissected at the same time.
The lipomas varied in size from 8-20 mm in diameter 
(Fig. 3.3:2-7), some with necrosis (Fig. 3.3:2 and Fig. 3.3:6) 
and some without apparent necrosis (Fig. 3.3:4-5 and Fig.
3.3:7). On cutting, hard white masses were revealed as seen 
in Fig. 3.3:8.
The degree of necrosis and inflammation varied widely 
in degree, from one lipoma to another (Fig. 3.3:11-17). Also, 
fat cell infiltration into the pancreas varied in degree and 
in one lipoma cholesterol clefts were seen (Fig. 3.3:17).
A small piece of each lipoma and pancreas was cut and 
immediately frozen by Arcton (Freon -22) at -158°C for 
immunocytochemical experiment. The remains were dissected 
and fixed in 10% formol saline for histological examination.
A block from each lipoma and pancreas was later processed in 
Histokinette, and embedded in paraffin wax. Sections were 
cut and stained by haematoxylin and eosin.
The histology of the head and the middle part of the. 
pancreas from both control and test obese mice was normal and 
showed the characteristic enlarged islets of Langerhans (Fig. 
3.3:9-10), of which about 90% islet cells appeared to be
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No 1 2 3 4
i
\ ;  ■_______
Fig. 3.3:1 Obese mice after weight reduction. Two test obese
mice after seven weeks of 72 hours fasting, 24 hours 
ad libitum feeding (Nos. 1, 4) one obese control 
(No. 2) and a lean control (No.3) are shown for 
comparison.
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Fig. 3.3:1 Obese mice after weight reduction. Two test obese
mice after seven weeks of 72 hours fasting, 24 hours 
ad libitum feeding (Nos. 1, 4) one obese control 
(No. 2) and a lean control (No.3) are shown for 
comparison.
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Fig 3.
P
; 2 A lipoma attached to pancreas from eight months 
old obese mouse, after seven weeks of three days 
fasting, one day feeding regime.
/
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Fig. 3.3:3 A lipoma attached to pancreas from eight 
months old obese mouse, after seven weeks 
of three days fasting, one day feeding regime.
Fig. 3.3 :4 A lipoma attached to pancreas from eight months 
old obese mouse, after seven weeks of three days 
fasting, one day feeding regime.
Fig. 3.3:5 A lipoma attached to pancreas from eight 
months old obese mouse, after seven weeks 
: of three days fasting, one day feeding regime
Fig. 3.3 ;6 A.necrotic lipoma attached to pancreas from 
an eight month old mouse after seven weeks 
of three days fasting, one day feeding regime.
Fig. 3.3:7-8 Large lipoma attached to pancreas )
from obese mouse after seven weeks of three 
days fasting one day feeding regime.
The lower figure shows cut surface of the 
lipoma.
Fig. 3.3;9 Pancreas showing islets, from obese mouse after 
seven weeks of three days fasting, one day 
feeding regime. The histological appearance is 
like that of the control mice CHE X 100).
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Fig. 3.3:10 High magnification of the islet cells from 
. the previous pancreas (HE X 400).
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Fig. 3.3:11 Necrotic lipoma with fibrous capsule and
inflammatory cell infiltration attached to 
the pancreas ( — ► ) (HE X 100).
IMI
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Fig. 3.3:12 Outline of necrotic fat cells (--> ) with
inflammatory ceil infiltration in another 
lipoma.
51 _
Fig. 3.3:13 High magnification of the previous lipomas 
showing necrotic fat cells CHE X 400)
P^fiS
Fig. 3.3:14 - Infiltration of fat cells into the pancreas
of obese mice after seven weeks of three days 
fasting,one day feeding regime CHE X 100)
- / 53_
V
Fig. 3.3:15 High magnification of exocrine pancreas with 
infiltrated fat cells from the previous mice. 
CHE X 400)
Fig. 3.3:16 Infiltration of fat cells into the pancreas 
from another obese mouse after seven weeks of three day 
fasting, one day feeding regime.
Fig. 3.3:17 High magnification showing focus of cholesterol 
clefts in a lipoma (HE X 400).
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active $cells (Gepts et al 1960; Heilman and Peterson I960, 
Heilman et al 1961; Heilman et al 1962; Renold, Orci,
Stauffacher, Junod and Rouiller 1970).
Histological examination of the tumours (Fig. 3.3:11-17) 
confirmed that they were all lipomas, attached to the 
pancreas. In some cases, fat cells infiltrated the pancreatic 
tissues (Fig. 3.3:14-17).
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2 - Discussion
It is known (Wills 1953, Morson and Dowson 1974) that 
lipomas occur naturally in mice. Nevertheless, the finding 
that six out of the twelve ob/ob mice, which were on a weight 
reducing regime for seven weeks (three days fasting, one day 
feeding) had lipomas attached to the pancreas in the same way, 
whilst none of the control mice, whether obese (12) or lean 
(12) mice had lipomas is highly significant.
It is not known whether lipomas were present in the 
other obese mice groups which had their weight reduced in the 
previous experiments (Section 3.2) as these mice were not 
dissected.
The presence of lipomas in obese hyperglycaemic mice is 
seen from time to time, but they are not usually attached to 
the pancreas, nor with such high incidence (Dr. M. Lancaster - 
personal communication, 1975).
A possible explanation for this phenomenon was given 
by Dr. Norman B. Gibbs (Consultant Pathologist, St. Luke's 
Hospital, Guildford) who suggested that lipomas arise at the 
tail of the pancreas as a result of pancreatic lipase lackage 
from the pancreas. Indeed, this is the explanation put 
forward for occurrence of lipomas in man, following inflammation 
of the pancreas (acute pancreatitis). It is now well recognised 
that pancreatic lipase attacks the adipose tissues around the 
pancreas causing fat necrosis and/or a rise to lipomas but, in 
my opinion, this still does not explain the mechanism of 
neoplastic transformation.
Whether alternate fasting and feeding .regime accelerate 
or precipitate the lackage of pancreatic lipase from the 
pancreas, should be investigated in further studies./
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3.4 The Possible Role of Gut Hormones in the Development 
of Obesity in Obese Hyperglycaemic Mice (ob/ob)
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Preparation of Materials for Histological and Immuno-
histochemical Experiments
Two sets of twenty obese hyperglycaemic mice aged four 
and eight months together with their littermates were chosen 
for this study. The choice of the two age groups was made 
following the observation of body weight changes of the mice 
with age as seen in Fig. 3.4:1.
By the time the experiment had begun, the older set of 
obese mice (eight months), had already reached their maximum 
weight, but the young mice (four months) were still gaining 
weight.
The two test groups of obese mice (ten mice per group) 
were kept for seven weeks on a 72 hours fasting, 24 hours 
ad libitum feeding regime (as described in Section 3.2). 
Whereas the matching lean (twenty mice) and obese controls 
(twenty mice) were fed ad libitum throughout. Body weight . 
changes in each group at the end of this experiment are 
summarised in Table 3.4:1.
Mice Group No.
Mean.
Body
Weight (g)
% Weight 
Changes
0 7 weeks
Young obese Test 10 91 47 -48.6
(4 months) Controls 10 95 97 + 2.0
Young lean Controls 10 34 35 + 2.8
Old obese Test 10 99 88 -11.1
(8 months) Controls 10 110 59 -47.5
Old lean Controls 10 36 38 + 5.2 
. ...... ....  _J
- loss: + gain
Table 3.4:1
Body weight changes of obese mice after seven weeks of 
72 hours fasting, 24 hours ad libitum feeding regime.
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Fig. 3. 4:1 Mean(± SEM) body weight of 30 obese 
hyperglycaemic mice (ob/ob) and 30 
lean mice of different ages, fed rat 
chow diet ad libitum
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At the end of the weight reduction period, the mice 
were killed, after an overnight fast, by cervial dislocation 
and tissues were taken from the antrum, pancreas, 7 cms of 
proximal duodenum, followed by the adjacent 7 cms of the 
upper jejunum. Then, missing about 5-7 cms length, a further 
7 cms were taken from the lower jejunum. A similar procedure 
was followed along the gut as far as the proximal colon.
Flat pieces of mucosa from each area were quenched in 
'Arcton5 (Freon-2.2) at -156°C each piece was kept in a 
plastic bag, labelled and kept in flasks containing solid CC^.
The materials were then sent in flasks (containing solid 
CC^) to Dr. J. Polak at the Department of Histochemistry, Royal 
Postgraduate Medical School, London. She kindly undertook 
to study the possible changes in the gut hormone producing 
cells in these mice as a result of weight and insulin reduction
by means of quantitative histology of silver stained preparation
which demonstrates the majority of endocrine cells and 
quantitative immunocytochemical studies by image analyser which 
determine the number and hormone content of the endocrine cells 
in the gut.
These techniques are described in detail by Pearse 1969; 
Pearse, Polak, Adams and Kendal 1974; Pearse and Polak 1975;
Polak, Pearse, Adams and Garaud 1974; Polak, Pearse, Garaud
and Bloom 1974; Polak, Pearse and Heath 1975b.
The histological and immunocytochemical studies 
described are still incomplete.
Discussion
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Body weight, blood glucose and plasma insulin levels of 
obese hyperglycaemic mice (ob/ob) were all markedly reduced, 
in a relatively short time, by alternate periods of fasting 
for 72 or 48 hours and refeeding for 24 hours. Physical 
activity increased significantly with the decrease in weight.
The mice regained weight on the resumption of normal feeding 
and the blood glucose and plasma insulin concentrations rose 
rapidly to their original levels.
Breeding from 'slim1 ob/ob mice was not possible. This 
finding is in contrast to the report by Lane and Dickie (1954), 
who used different slimming regime. The' results suggest that 
failure to breed even from 'slim' ob/ob mice, is not due to 
obesity as such, but to another primary abnormality, causing 
irregular and infrequent cycling periods in the female ob/ob 
mouse, and marked reduction volume and nuclar size of Leydig 
cells in the male mouse (Coleman and Hummel 1968; Lidell and 
Heilman 1966; Heilman, Jacobsen and Taljedal 1963).
The finding of a significant increased incidence of 
lipomas (some with necrosis) attached to the tail of the 
pancreas, in ob/ob mice after seven weeks on a weight reduction 
regime of 72 hours fasting, 24 hours ad libitum feeding 
(Section 3.3) was not expected and should be further investigated
It is possible that the alternate fasting and refeeding 
regime which caused changes in blood glucose and plasma 
insulin levels could also cause leakage of pancreatic lipase 
from the pancreas giving rise to fat necrosis and lipomas at 
the tail of the pancreas.
Fatty infiltration of the pancreas, with an increase in 
the amount of *intestinal fat, is common in cases of human 
obesity (Anderson 1961). However, this is not usually 
associated with lipomas. / >
Whether alternate fasting and refeeding regimes 
accelerate or precipitate the leakage of the pancreatic lipase 
from the pancreas, should be investigated in further studies.
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Certainly the alternate fasting and refeeding regime 
employed in the present study were well tolerated by the obese 
mice and were effective in producing marked and progressive 
weight loss without apparent ill effect.
Treatment with varying doses of triiodothyronine (T3) 
failed to cause significant weight loss in ob/ob mice with 
free access to food. This is consistent with the finding of 
normal thyroid status in ob/ob mice (Goldberg and Mayer 1952; 
Wykes et al 1958; Brav and York 1971).
The suggestion by Joosten and Van der Kroom (1974) , that
the obesity of the ob/ob mice is due to hypothyroidism receives
no support from the present work. This does not, however, 
preclude the possible involvement of other hormonal factors.
The rapid increase in overnight fasting blood glucose 
and plasma insulin during normal feeding of:1 slim* ob/ob mice 
(8-11 weeks Section 3.2) suggests that both :are secondary 
manifestation of a primary cause (hyperphagia), which is 
responsible for the obese hyperglycaemic syndrome.
The possibility has been entertained in the past that 
excessive secretion of insulin, due to an intrinsic 
abnormality of 3-cell function, might be the initial cause of 
obesity in ob/ob mice. Excessive secretion of insulin has 
also been held to be responsible for some cases of human
obesity (Marks and Samols 1968).
A serious objection to any hypothesis assigning a 
causative role to hyperinsulinaemia due to a primary 3-cell 
abnormality, however, is the fact that dietary induced weight 
loss both in human subjects and experimental animals is 
accompanied by a rapid fall in plasma insulin levels. These 
may reach normal yalues - both in the fasting and fed-state, - 
long before normal weight has been restored and whilst 
substantial adiposity is still present.
This latter observation makes it equally difficult to 
explain an alternative theory linking obesity with hyper-
■ ' ' “ 63 “ ■ '
insulinism, namely that obesity causes insulin resistance, 
and hence the necessity to secrete excessive amounts of 
insulin to maintain normal glucose homeostasis. Whilst 
both hypotheses may be correct - in some cases - the third 
possibility that both obesity and hyperinsulinism are a 
consequence ofthe same primary cause - namely hyper­
alimentation with consequent over-stimulation of the 
intestinal insulin release factors - has until recently received 
little attention (Fig. 3.5:1).
Evidence that gut insulin releasing factors can exert 
a priming effect upon the 3-cells of the pancreas, as well as 
stimulating them to secrete insulin directly, has been 
produced by Turner and Young (1973). Moreover, the hypothesis 
that primary over-production of intestinal hormones is 
responsible for the hyperinsulinaemia is consistent with 
evidence recently obtained (Polak et al 1975b), that the 
intestinal endocrine cells, shewn to be capable of secreting 
insulin releasing polypeptide hormones, gastric inhibitory 
polypeptide (GIP) and glucagon-like immunoreactivity (GLI), are 
greatly increased in number in ob/ob mice compared with normal 
weight (lean) litterates.
Whether a prolonged period of hypoalimentation produces 
a reduction in the intestinal endocrine cells and so accounts 
for the reduction in basal and glucose stimulated insulin 
release from the 3-cells is currently under investigation 
(Section 3.4).
The amino acids sequence of intestinal insulin releasing 
polypeptide (IRP) is not known, since IRP has yet to be isolated 
in a pure enough form. Although IRP preparations did not 
significantly cross-react with anti GIP-antibody (Turner et al 
1974 a,b) this does not preclude the possibility that IRP 
preparations are contaminated with GIP, which may be - ,
responsible for the insulin releasing activity of the crude 
IRP preparations.
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The hypothesis, suggested by Professor V. Marks 
linking gut hormones, insulin secretion and obesity, which 
is summarised in Figs. 3.5:1-3, appear at present to be a 
possible mechanism in the development of obesity.
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HYPOTHESIS FOR DEVELOPMENT OF OBESITY AND
SEQUENCE OF MECHANISM*
Hyperphagia
■I ' ' -  ■ '
HyperalimentationI
Hypertrophy of entro-endocrine cells
. 1 .Hyper lnsulxmsmI
Obesity
v  Fig. 3.5:1
*Courtesy of Professor V. Marks
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POSSIBLE INVOLVEMENT OF GUT HORMONES GIP, GLI AND IRP IN
PATHOGENESIS OF OBESITY (HYPOTHETICAL)*
1. Over-production of GIP, GLI and/or IRP in the cause 
of insulin over-production.
(i) by direct action of 3-cells
(ii) priming effect on 3-cells.
2. Hypersecretion of gut hormones is due to
(a) excessive stimulation of gut hormones,
secondary to high concentration of IRP, 
GIP releasing sugars in human gut
(b) inherited hypersensitivity of gut
hormones releasing mechanism.
Fig. 3.5:2
*After Professor V. Marks
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HYPOTHESIS LINKING INSULIN SECRETION AND OBESITY*
1. Increased insulin secretion is the prime 
mover and key factor in the pathogenesis 
of 'some cases of1 human obesity.
2. The increase in insulin secretion is itself 
secondary to increased secretion of 
intestinal hormones including the intestinal 
insulin releasing polypeptide (IRP) described 
by Turner, gastric inhibitory polypeptide 
(GIP) described by Brown and gut glucagon 
cross reacting materials (glucagon-like 
immunoreactivity, GLI, enteroglucagon) 
described by Samols.
Fig. 3.5:3
*After Professor V. Marks
C H A P T E R  4
GENERAL DISCUSSION
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The rather close association between obesity, diabetes 
and hyperlipaemia is well known (Kannel el al 1967). It is 
thought that the association between obesity and diabetes is 
caused by peripheral insulin ineffectiveness leading to insulin 
over production (Perley and Kipnis 1966).
Obese hyperglycaemic mice (ob/ob) provide an interesting 
model of diabetes, in that they present at the same time, 
obesity, hyperglycaemia and hyperinsulinaemia. It thus has 
several characteristics in common with human maturity onset 
diabetes (Vague and Boyer 1974).
The experiments performed on the obese mice have shed 
some light on the nature of the mechanisms involved in the 
development of obese hyperglycaemic syndrome.
The important finding of significant hyperplasia of 
the GIP cells in the gut of ob/ob mice CPolak et al 1975a) 
is open to a number of explanations. This hyperplasia may 
be primary (.genetic) or secondary. If the latter case 
applies, then the following causes should be considered.
1. Increased food intake (Bray and York 1971) with over­
stimulation of GIP cells.
2. Increased intestinal absorption of glucose (Mayer and
Yannoni 1956) .
*3. Glucose-mediated release of GIP with overdriving of
the cells.
4. Increased synthesis of GIP in response to requirement
for increased insulin output to balance high serum 
glucose levels, since GIP is an insulin releasing 
hormone (Dupre et al 1973, Turner et al 1974 a, b).
It is possible that another insulin releasing gut poly­
peptide IRP (Turner et al 1974 a, b; Shabaan et al 1974 a,b) 
could be concerned wTith production of the syndrome.
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It is hoped that the histochemical studies which 
have already started to look at the gut of ob/ob mice which 
had their weight reduced would.confirm the role of the gut 
hormones in the development of obese hyperglycaemic syndrome.
The recent evidence by Heptner and his colleagues (1975) 
shows that intragastric administration of glibenclamide causes 
the release of gut hormones effective in stimulating insulin 
release, suggests that in maturity onset diabetes, the typical 
pattern in serum insulin following the intake of food 
components, might be primarily due to a certain defect in the 
gastrointestinal tract rather than in the 3-cells of the 
pancreas itself.
The alternate fasting and refeeding regimes which were 
effective in producing rapid and progressive weight loss in 
ob/ob mice, might also form an acceptable basis for dietary 
therapy in some forms of human obesity. Duncan and his 
colleagues (1962, 1963) have used an initial period of fasting 
for a week or two, followed by one or two day fasts, to 
maintain weight loss or promote further weight loss. In 
view of the practical difficulties encountered in the treatment 
of obese subjects by long periods of complete starvation, the 
alternate 48 hours fasting, 24 hours feeding regime might be 
an easier alternative.
Obese hyperglycaemic mice (ob/ob) and hyperlipaemic 
rats, induced by cobalt chloride have been proven to be 
useful experimental models in studying obesity and hyperlipaemia.
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The Effect of an Intestinal Polypeptide Fraction on Insulin 
Release in the Rat in Vitro and in Vivo
D. S. TU R N ER , A. SHABAAN, LAURAINE ETH ERIDG E, a n d  V. MARKS
Departm ent of Biochemistry, University of Surrey, Guildford, Surrey, England
ABSTRACT. The effect of insulin release in the 
rat in response to a partially purified intestinal 
polypeptide fraction, “Intestinal Insulin Releasing 
Polypeptide (IRP),” has been studied in vivo and 
in vitro. It potentiated the release of insulin in 
response to 16.7 mM glucose and 16.7 nai leucine 
in rat pancreas pieces incubated in vitro, but had 
no effect on insulin release in the presence of 3.3 
mM glucose.
IRP produced a small increase in the insulin 
secretory response to the intravenous administra­
tion of an amino acid mixture, but the effect was 
not statistically significant.
A mixture of secretin and pancreozymin, 1 
U/kg of each, potentiated the plasma insulin re­
sponse to intravenous glucose, but to a smaller 
degree than IRP and did not accelerate glucose 
disappearance. Secretin studied in a similar man­
ner showed no insulin releasing effect at doses up 
to 2 U/kg.
IRP contains less than 4 U/mg secretin activ­
ity; no detectable pancreozymin or cholecystokinin 
activity and no significant contamination by GLI. 
It is concluded, therefore, that the insulin releas­
ing activity of this preparation is not due to any 
of these factors— separately or in combination—  
but to a previously uncharacterised polypeptide 
now isolated from the small intestine. (Endocri­
nology 93: 1323, 1973)
AN  INTESTINAL hormonal mechanism has been proposed for the regulation 
of insulin release following oral glucose ad­
ministration (1 ). It has been suggested that 
this hormonal activity is not attributable to 
the known intestinal polypeptide hormones 
secretin or pancreozymin, or to the gluca- 
gon-like immunoreactive material found in 
the gastrointestinal tract (2 ).
A polypeptide fraction to which the name 
“Intestinal Insulin Releasing Polypeptide 
(IR P )” has been given, has been isolated 
from porcine duodenojejunal mucosa (3 ). 
This preparation, when injected at the same 
time as an intravenous glucose load resulted 
in a marked enhancement of both the 
plasma insulin response and glucose disap­
pearance in the rat (4 ) . N o effect was ob­
served when it was administered with an 
intravenous injection of physiological saline 
solution. Further studies of the insulin re­
leasing effects of IR P in vitro and in vivo 
are reported here.
Received February 15, 1973.
Materials and Methods
In testin a l insulin-releasing p o lyp ep tid e , I R P
The partially purified intestinal extract, IRP, 
was prepared by the acid ethanol extraction of 
frozen porcine duodenojejunal mucosa.
The initial extraction was based on the pro­
cedure used for the preparation of material with 
glucagon-like biological activity from human 
intestine (5).
Frozen porcine duodenojejunal mucosa was 
extracted with acid ethanol (ethanol, water, 
conc. HA. 75:25:1.5), 5 ml per g wet tissue. 
After homogenizing in a Waring blender the 
mixture was kept for 2 hr at 4 C and then cen­
trifuged at 2,000 rpm for 15 min. The super­
natant was retained and the pellets re-extracted 
with 3 ml/g of starting material and kept over­
night at 4 C. The mixture was centrifuged at
2,000 rpm for 15 min and the supernatant com­
bined with that from the first extraction. The 
pH was adjusted to 7.8 by the addition of con­
centrated ammonia solution. After standing for 
2 hr the precipitate was removed by centri­
fugation at 2,000 rpm for 15 min. To each liter 
of supernatant was added 1.7 1 of ice-cold ethanol 
and 2.8 1 of ice-cold peroxide-free diethyl ether. 
After standing overnight at 4 C the precipitate
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was collected by centrifugation at 2,000 rpm 
for IS min. The precipitate was dried under a 
stream of nitrogen.
The ethanol-ether precipitate was then dis­
solved in 0.1m  acetic acid, 2 g in 50 ml and 
dialysed in visking 18/32" tubing against 0.1m  
acetic acid at 4 C for 48 hr. The retentate was 
chromatographed on a column of Sephadex G50 
fine, 5 X 85 cm in 0.1m  acetic acid and the 
effluent eluted between Kd 0.3 to 0.93 was then 
passed through a column of carboxymethyl cel­
lulose, Whatman CM52, 2.5 X IS cm, equili­
brated in 0 .1 m  acetic acid. The column was 
then washed with 200 ml 0.1m  acetic acid, fol­
lowed by 200 ml 0.3m  acetic acid. A protein 
peak was then eluted by 0.2m  sodium chloride 
in 0.3m  acetic acid. This peak was freeze dried 
and then desalted using a 2.5 X 85 cm column 
of sephadex G10 in 0.1m  acetic acid and freeze 
dried.
The IRP preparation was tested for insulin- 
releasing activity by intravenous injection into 
rats with glucose and demonstrating an increase 
in the 5-min plasma insulin level following in­
jection compared with that following the injec­
tion of glucose alone, as described below under 
in vivo procedures.
The UV absorption characteristics of the ma­
terial indicate a proteinaceous character and its 
molecular weight is probably of the order 
3-4,000. Iso-electrofocusing shows a basic 
character (3).
Glucagon-like immunoreactive material (GLI) 
was assayed by Dr. S. R. Bloom of the Middle­
sex Hospital Medical School, London, and by 
Dr. K. D. Buchanan of the Queen’s University, 
Belfast, using antisera raised against glucagon, 
but which cross-reacted equally well with enteric 
GLI. The highest estimate of GLI content was 
equivalent to 15 ng pancreatic glucagon per mg 
IRP. Batch G4 was tested by Dr. Viktor Mutt, 
of the Karolinska Institute, Stockholm and con­
tained the equivalent of between 1 and 4 U 
secretin per mg IRP. No pancreozymin or 
cholecystokinin activity was detected. Batch A 
was assayed for secretin biological activity by 
Mr. V. D. Birkinshaw of Boots Pure Drug Com­
pany Ltd., Nottingham and found to contain 
the equivalent of 0.5 U secretin per mg IRP.
In vitro procedures
Rats were fasted overnight and killed by de­
capitation. The pancreas was removed, washed
in ice-cold Krebs Ringer bicarbonate solution 
and dissected free of extraneous tissues in ice- 
cold incubation medium. Each pancreas was 
cut into 12 pieces, placed in a flask containing 
6 ml Krebs Ringer Bicarbonate containing glu­
cose, 3.3mM  and incubated in a shaking water 
batch for 30  min at 37 C in an atmosphere of 
9 5%  oxygen, 5%  carbon dioxide. The buffer 
incorporated Trasylol®, a proteinase inhibitor, 
250 KlU/ml.
At the end of 30 min the pancreas pieces 
were transferred to new flasks containing 6 ml 
incubation medium at the glucose concentration 
required for the experiment and incubated for 
a further 15 min.
Twelve flasks were prepared, each containing 
3 ml incubation medium with the appropriate 
glucose concentration. Six flasks contained no 
addition to the medium and served as controls. 
The other six contained the material under test 
for insulin-releasing activity. A piece of pancreas 
from four different rats was placed in each flask 
and the flasks incubated for 30 min. The pan­
creas pieces were weighed and the insulin con­
tent of the incubation medium measured by 
radioimmunossay. Insulin values were expressed 
as fxU/ml insulin/mg pancreas/30 min.
The results of each set of 6 flasks were ex­
pressed as a percentage of the mean value for 
the 6 control flasks. The statistical significance 
of the values obtained was assessed by use of 
the Student’s t test using Bessel’s and Aspin- 
Welch corrections, except for cases in which 
the variance ratio required the use of the F- 
distribution.
In vivo procedures
Overnight-fasted Wistar rats weighing 300- 
350 g were used. Each rat was weighed and 
anaesthetized with sodium pentobarbitone 
(Nembutal®) 3.5-4.0 mg/100 g body wt. The 
Nembutal was diluted in saline to a concentra­
tion of 6 mg/ml and injected ip. Blood samples 
were obtained by cutting the tip of the tail and 
milking the tail vein.
Samples for glucose estimation were collected 
in 0.05 ml capillary pipettes and discharged 
into 0.95 ml 2% w /v perchloric acid.
Blood for insulin assay was collected into 
heparinized microcentrifuge tubes (Gelman- 
Hawkesley) and kept on ice until centrifuged. 
The centrifuge tubes were stored upright at
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—15 C and the portion of the tube containing 
plasma cut off when required for use.
Glucose (0.625 g/kg body wt) was injected 
into the femoral vein as a 12.5% w /v solution 
over a period of 1 2^ min. IRP and other test 
substances were dissolved in 12.5% glucose sol­
ution for injection.
The amino acid mixture used for intravenous 
injection was a 10% w /v solution of hydroly­
sate (Aminosol®) Vitrunn Co., Sweden).
Glucose was measured by a glucose oxidase 
procedure using the Boehringer kit. Plasma 
insulin was measured using a double antibody 
radioimmunoassay procedure (6).
Results
Effect of IR P  on rat pancreas pieces in 
vitro
The results and conditions of each test 
are listed in Table 1. IRP, 0.1 m g/m l was 
without effect on insulin release from pan­
creas pieces incubated at a glucose concen­
tration of 3.3 m M , but significantly poten­
tiated insulin release when incubated with 
16.7 m M  glucose. A smaller but significant 
stimulation of insulin release was seen when 
IRP was added to pancreas pieces incu­
bated with 16.7 m M  L-leucine.
Effect of secretin and pancreozymin on rat 
pancreas in vitro
Secretin and pancreozymin were used in 
combination in the rat pancreas piece 
preparation at a concentration of 1 U /m l of 
each. N o significant effect on insulin release
was observed in the presence of either 3.3 
m M  glucose or 16.7 m M  glucose.
1. Effect of IR P  on amino acid induced 
insulin release in vivo
Mean blood glucose and plasma insulin 
levels resulting from this experiment in two 
groups of eight animals are shown in Fig. 1. 
There was a greater rise in plasma insulin 
in rats given protein hydrolysate plus IRP  
than in those given protein hydrolysate alone 
but the difference was not significant (p >  
0.05 <  0 .1).
2. Effect of secretin-pancreozymin in com­
bination on response to intravenous glucose
Mean blood glucose and plasma insulin 
values in two groups of eight rats given 
either glucose or glucose plus secretin and 
pancreozymin are shown in Fig. 2. Blood 
glucose levels differed significantly only at 
30 min (p <  0.05), when they were lower 
in animals given secretin and pancreozymin 
in addition to glucose than in those given 
glucose alone. Peak plasma insulin levels 
at 5 min were significantly higher (p <  
0.001) in animals receiving secretin and 
pancreozymin (238 ±  16.3 pU /m l) than 
in those receiving glucose alone (136 ±  
7.9 pU /m l). Differences at other times 
were not significant.
T able 1.
No. of Insulin release p value difference 
Incubation conditions flasks as %  control from control
Glucose 3.3 mM 12 100 ± 10.723
Glucose 3.3 mM plus IRP 0.1 mg/ml 12 118.66 dr 16.91 >0.15
Glucose 16.7 mM 12 100 dr 14.664 *
Glucose 16.7 mM plus IRP 0.1 mg/ml 12 287.07 dr 66.337 <0.01
Glucose 3.3 mM, Leucine, 16.7 mM 6 100 dr 13.253
Glucose 3.3 mM, Leucine, 16.7 mM plus IRP 0.1 mg/ml 6 146.66 ± 17.255 <0.025
Glucose 3.3 mM 6 100 dr 15.13
Glucose 3.3 mM plus secretin and pancreozymin 1.0 U/ml 6 68.67 dr 13.30 p > 0.05
Glucose 16.7 mM 6 100 dr 16.78
Glucose 16.7 mM plus secretin and pancreozymin 1 U/ml 6 126.39 dr 18.08 p > 0.15
* By F distribution.
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InsulinGlucose
200
300
•  Aminosol
A Aminosol + IRP
150
200
pU/mlmg%
100100
Minutes post infusion
Fig. 1. Effect of IRP (0.5 
mg/kg) on plasma insulin and 
blood glucose response to in­
travenous amino acids. A 10% 
w/v solution of casein hydrol­
ysate (Aminosol®) was given, 
5 ml/kg body weight. IRP 
(batch G4) was dissolved to 
give a concentration of 0.1
mg/ml. ------ • -------  mean ±
alone; ---▲---mean ±
sem in 8 rats given aminosol 
plus IRP.
3. Effect of secretin plus pancreozymin 
administered with intravenous saline so­
lution
Mean blood glucose and plasma insulin 
levels in six rats given saline alone iv and 
rats given saline plus secretin and pan­
creozymin are shown in Fig. 3. There was 
no significant difference between glucose 
and insulin levels in the two groups.
4. Dose response to IR P
The curve obtained by plotting glucose 
dependent insulin releasing activity as a 
percentage of control values against dose is 
shown in Fig. 4. These data were obtained 
by measuring plasma insulin values S min 
after the administration of glucose or glu­
cose plus IRP. Significant augmentation of 
insulin release (p <  0.01) was demon­
strated by the smallest dose level used in
this experiment, 62.5 ng IR P /k g  body wt. 
Increasing the dose increased the response 
and there was a tendency to. saturation. A 
plot of glucose dependent insulin-releasing 
activity against log dose is shown in Fig. 5.
5. Dose response to secretin
The plasma insulin response at 5 min to 
the addition of four doses of secretin to 
glucose injections under the same condi­
tions as used to test the dose response to 
IR P are shown in Fig. 4. At no dose was 
there a significant insulin-reaching effect.
Discussion
The active component of the partially 
purified IRP preparation used in the pres­
ent studies possesses the property of poten­
tiating glucose-stimulated insulin release 
in the rat. It has no effect on insulin re­
lease at basal blood glucose concentrations.
InsulinGlucose
•  Glucose
A Glucose + SEC + PZ
200
300
pU/ml
150
200
mg%
100 100  -±
60 0 5 10
Minutes post infusion
60
F ig .  2. Effect of secretin (0.5 
U/kg) plus pancreozymin (0.5 
U/kg) on the plasma insulin 
and blood glucose response to 
intravenous glucose. 12.5% 
w/v glucose solution was 
given, 5 ml/kg body wt. Se­
cretin and pancreozymin were 
dissolved in the glucose solu­
tion to give a concentration of
0.1 U/ml of each hormone.
 • mean ± sem in 8
rats given glucose alone;
 A mean ±  sem in 8
rats given glucose plus secretin 
and pancreozymin.
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F ig .  3. Effect of secretin (0.5 
U/kg) plus pancreozymin (0.5 
U/kg) at basal blood glucose 
concentrations. 0.9% saline 
was given intravenously, 5 
ml/kg body wt. Secretin and 
pancreozymin were dissolved 
in saline to give a concentra­
tion of 0.1 U/ml of each hor­
mone. ---•--- mean ±
sem in 8 rats receiving saline
alone; ▲— - mean ±
sem in 8 rats given saline plus 
secretin and pancreozymin.
Similar effects are observed both in vitro 
and in vivo. Thus, the behavior of IR P with 
respect to glucose-stimulated insulin release 
in the rat corresponds to that postulated 
(2) for an hypothetical intestinal hormone 
designated “Incretin” but now referred 
to as “Glucose-dependent insulin-releasing 
hormone (G IR H )”— which wrfuld be re­
sponsible for the greater insulin secretory 
response to oral as compared to intravenous 
glucose (1 ). These findings are in agree­
ment with earlier reports (2 ,7) showing 
potentiation of glucose-stimulated insulin 
release in vitro by extracts prepared from 
porcine intestine.
A less marked augmentation j of amino
Glucose Insulin
•  Saline
a Saline + SEC + PZ150
(iU/mlmg%:
100
Minutes post infusion
acid-stimulated insulin release is* shown by
GIRA
200
A SECRETIN
100
units/kg  SECRETIN 
2-°  m g/kg IRP
F ig .  4. Dose-response to IRP and secretin in rats 
given intravenous glucose. Each animal received 5 
ml/kg body wt of a 12.5% w/w glucose solution 
containing IRP or secretin at the dose indicated. 
Each point is the mean ± sem of the plasma insulin 
level at 5 min after the injection for 8 rats.
 •-- IRP;----A---Secretin; %  GIRA
represents glucose dependent insulin-releasing activ­
ity as a percentage of the mean control value for 
glucose alone.
IR P in vitro  and in vivo. The fact that this 
response is much smaller than that pro­
duced in the presence of hyperglycaemia 
may indicate that IR P does not exert a 
significant effect on amino acid-stimulated 
insulin release under physiological condi­
tions. A stronger candidate for that role 
would be pancreozymin (2 ,8).
The results of dose-response experiments 
show a curve typical of many biologically 
active agents. The lowest dose of IR P used 
in the present series of experiments was 
62.5 pg IR P /k g  body wt. This was suf­
ficient to produce a significant effect on 
insulin release. Since the IR P  preparation 
used in these studies was relatively crude 
it is probable that much smaller doses of 
pure IR P would evoke a significant insu- 
linemic response.
The log-linear dose response to IR P ob-
GIRA
300
r  = 0.9958
P <  0.001200
100
.0625 0.125 0.25 0.5 1.0
d o se  m g /k g  ( log s c a le  )
F ig .  5. Dose-response to IRP. The same data for 
dose-response to IRP as shown in Fig. 4 are plotted 
against log-dose of IRP.
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tained in vivo  may provide the basis of a 
quantitative bioassay for IR P activity.
The action of secretin and pancreozymin 
in combination was similar to that of IRP, 
with two important exceptions. First, IRP  
at a dose of 0.5 m g/kg body wt produced 
a marked reactive hypoglycaemia after 45 
min, whereas secretin plus pancreozymin 
did not. Secondly, the peak mean plasma 
insulin level produced by glucose plus 
secretin and pancreozymin was lower than 
that produced by glucose and IRP, 0.5 
m g/kg body weight. This experiment was 
performed to examine the possibility that 
the insulin-releasing activity of IR P might 
be accounted for by the combined action of 
secretin and pancreozymin contaminants. 
This would seem to be most unlikely, how­
ever, in view of the low content of secretin 
biological activity of IR P and the absence 
of pancreozymin or cholecystokinin activity. 
Secretin alone in quantities up to and in­
cluding the maximum level of secretin con­
tamination of IR P had no significant effect 
on 5-min plasma insulin levels in vivo. The 
failure of secretin and pancreozymin to 
stimulate insulin release in vitro is consis­
tent with earlier observations made with 
the two hormones separately (2,9,10). 
Other studies (11,12,13) have reported 
secretin and pancreozymin stimulation of 
insulin release in vitro , but their effect does 
not appear to be related to glucose concen­
tration. It seems exceedingly unlikely that 
secretin and pancreozymin either separately, 
or in combination, are responsible for the 
insulin-releasing activity of IRP.
There is increasing evidence (9,14,15) 
that gut GLI does not possess insulin-releas­
ing activity. It seems unlikely, therefore, 
that the small content of GLI in the IRP  
preparations contributed to its insulin- 
releasing activity.
Gastric Inhibitory Polypeptide (G IP) re­
cently purified from porcine duodenum (16) 
has been found to augment glucose-estimated 
insulin release. It is not yet possible to relate 
the activity of this peptide to the findings 
discussed here.
The degree to which IR P potentiates glu­
cose-stimulated insulin release is sufficient 
to account for the greater insulin-releasing 
potency of oral as compared to intravenous 
glucose. It is likely, therefore, that the active 
component of IR P is the hormone proposed 
for the intestinal regulation of glucose- 
stimulated insulin release.
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SUMMARY
In a study of the long term effects of cobalt chloride '(CoQ^) 
in the rat hyperlipaemia persisted for more than 12 months.
Nine out of 20 cobalt chloride treated rats and one control 
rat died within the first year and eight out of the surviving animals 
developed fibrosarcomas. In four of the animals the tumour was far 
removed from the injection sites.
The results are discussed with reference to the use of cobalt 
chloride treatment for anaemia in patients with chronic renal failure.
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cultured islets and the stimulatory action seemed to be enhanced as 
the glucose concentration of the culture medium increased. — It is 
concluded that exposure of isolated pancratic islets for one week to 
a high glucose concentration causes an exaggerated glucagon 
response to both arginine and glucose. It remains unclear to what 
extent this is due to the high insulin concentration present in the 
culture system.
250. Glucose Effects on Calcium Fluxes in Pancreatic Islets, Using 
Lanthanum to Distinguish between Superficial and Intracellular 
Pools.
J. Sehlin. The University of Ume£, Department of Histology, S-901 
87 UmeS, Sweden.
Fluexes of 45Ca2 ^ were studied in islets from ob/ob-mice. La3+ 
blocked both influx and efflux of 45Ca2+; in studies of intracellular 
43Ca2+ the islets were washed with 2 mM La3+ for 1 hour after 
incubation. The uptake of 45Ca2+ in islets ixposed to 3 mM 
D-glucose reached an apparent equilibrium after 2 hours at which 
time the intracellular concentration of exchangable Ca2+ was about 
7 mmol/kg dry weight (with 2.6 mM Ca2+ in medium). Raising the 
D-glucose concentration to 20 mM enhanced the 43Ca2+ uptake 
whether or not the islets had first been equilibrated with the isotope. 
The effect could not be reproduced with equimolar L-glucose. — 
The rate of release of intracellular 45Ca2+ was the same whether the 
islets had been preloaded with 3 or 20 mM D-glucose; halftime for 
release was 30 min. Thus, 45Ca2+ that had been taken up in response 
to 20 mM D-glucose appeared to be released much more slowly 
than the bulk of intracellular 45Ca2+. — It is concluded that 20 mM 
D-glucose caused a net uptake of Ca2+ into the /5-cells. This uptake 
was probably hot regulated at the level of the plasma membrane but 
more likely reflected an increased affinity of some intracellular 
compartment for the ion.
251. A Computer Evaluation System for the Study of the Natural 
History of Diabetes.
H.K. Selbmann, W. Kreutzfeld, K. Schoffling, K. Oberla. Univ. 
Miinchen, Inst. f. med. Informationsverarb., Statistik, Univ. 
Gottingen, Med. Klinik und Poliklinik, Univ. Frankfurt, Zentrum 
der Inneren Medizin, Abt. Endokrinologie, FRG.
A retrospective study of 1302 diabetics was conducted in the out­
patient departments of the Universities of Frankfurt and Gottingen. 
The patients were observed every year, over a period starting usual­
ly with the year of diabetes recognition, and ending with the closing 
date of the study in 1971. So approximately 11,000 years of diabetic 
life directly observed are available for statistical analyses. An effi­
cient evaluation of such large volumes of data can only be done by 
computer information systems. The presented system SAVOD-L 
allows the statistical evaluation of the data in a dialogue with the 
computer. The immediate answering of an open list of questions in 
form of frequency information, histogrammes, crossclassification 
tables or survival curves enables an intensive exploitation of the 
data. — The features of the information system are demonstrated 
on a display terminal located in the congress area. This terminal is 
connected with the computer of the medical faculty of the Universi­
ty of Munich. So the participants of the congress have the 
opportunity to ask questions directly of the information system.
252. Elevations of Sorbitol and Myoinositol in Diabetic and 
Nondiabetic Patients Who Have Impaired Renal Function.
C. Servo, E. Pitkanen. IV Department of Internal Medicine, Uni­
versity of Helsinki, SF-00170 Helsinki, 17, Finland.
We studied the mechanisms responsible for elevations in con­
centrations of sorbitol in diabetes and myoinositol in uremia. — 
Concentrations of polyols were determined by gas-liquid 
chromatography in plasma, red cells or cerebrospinal fluid (CSF), 
or in all three; 10 diabetic patients with nephropathy, 10 non-diabe­
tic uremic patients and 14 non-diabetic patients on dialysis were 
studied. Levels of sorbitol were significantly elevated (p 0.01) in 
CSF of diabetic patients and in red cells of both diabetic and 
dialyzed patients, an observation not previously reported. During 
dialysis red cell sorbitol levels rose by 20%. — Concentrations of 
myoinositol, normally elevated in CSF, were highest in plasma of
almost all patients, a finding which in uremic patients correlated 
negatively with creatinine clearance. During dialysis, plasma levels 
fell by 45 — 80% and red cell levels by 0— 15 %. — Our results show 
that difference in osmolar gradients between red cell and plasma 
polyols were too small to cause intracellular damage and that 
elevations in levels of CSF-sorbitol were caused by synthesis in situ 
and not by the uremic state. Elevations of myoinositol in uremia 
were likely to result from tissue retention and impaired degradation 
in the kidneys and seem therefore to be an index of kidney damage.
£/253. The Role of Pancreas in Hyperlipaemic Rats.
A. A. Shabaan, V. Marks. Department of Biochemistry, University 
of Surrey, Guildord, Surrey. GU2 5XH., U. K.
Experimental hyperlipaemiai produced in the rat by cobalt chloride 
(CoCl2) injection can serve as a model for studying the mechanism 
and the factors involved in human hyperlipaemia. — Rats were 
made hyerlipaemic by subcutaneous injection of CoCl2. Tissue dis­
tribution of cobalt was studied by injection of radioactive cobalt 
(57Co). Hepatocytes from cobalt chloride treated and control rats 
were studied and compared in monolayer tissue cultures. — The 
pancreas contained more cobalt than any other tissue apart from the 
liver and kidneys and the islets showed evidence of histological 
damage. Glucose uptake by hepatocytes isolated from the CoCl2 
treated rats was unaffected by addition of either insulin or glucagon 
in contrast to hepatocytes isolated from untreated controls. — 
CoCl2 induced hyperlipaemia is associated with abnormal control of 
carbohydrate metabolism in the liver, possibly secondary to islet cell 
damage.
254. Effect of Insulin on Activity of Lipogenesis Enzymes and 
Growth of Cultured Human Fibroblasts.
E. Shafrir, E. L. Bierman. Department of Medicine, University of 
Washington School of Medicine, Seattle, Washington, US A.
Since little is known about the regulation of lipogenesis in human 
tissues, the capactiy of fatty acid synthesis in human skin fibroblasts 
has been assessed. The fibroblasts, obtained from normal adult 
donors, were grown to confluency in a modified Duibecco’s medi­
um. The medium was then replaced with a fresh one containing 
10% fetal calf serum made lipoprotein free by ultracentrifugation at 
d = 1.25 and free fatty acid free by charcoal absorption. From 20 
pU/ml to 20,000 pU/ml of purified single component insulin (Lilly) 
were added and the cells incubated for 3 days. Proliferation of cells 
was discernible even at the lowest insulin concentration and a linear 
relationship between log of insulin concentration and cell growth 
was apparent. In the presence of 2,000 pU/ml growth was increased 
by 28 to 45% with various cell strains. — The activity of the 
rate-limiting enzyme of fatty acid synthesis, acetyl-CoA 
carboxylase was determined in 100,000 g supernatant fraction, by 
fixation of 14C02 after maximal activation with citrate. The activity 
ranged from 0.15 to 0.80 nmol • min-1 • mg-1 of soluble protein in 
various cell strains compared to 1 and 24 nmol • min-1 • mg-1 in 
human subcutaneous and rat epididymal adipose tissues, 
respectively. Increasing amounts of insulin induced a gradual rise in 
enzyme activity independent of the increase in cell number. At
2,000 pU/ml for 3 days, the activity rose 1.5 to 4-fold when 
expressed per cell, or per protein or DNA content. Likewise, insulin 
induced increases in the activity of other regulatory enzymes of 
lipogenesis, ATP-citrate lyase, NADP-malate dehydrogenase and 
fatty acid synthetase. The activity of the enzymes and the extent of 
induction tended to decrease after multiple passages of cells in 
culture. The presence of fatty acid synthetic enzymes and their 
amenability to insulin induction, in a fashion similar to that in liver 
and adipose tissue of experimental animals, render the cultured 
fibroblasts a convenient model living system for the study of regula­
tion of lipogenesis in man.
255. A Possible Role of Glucagon in the Mechanism of Somatos­
tatin — Induced Inhibition of Insulin Release.
J. Sieradzki, H. Schatz, C. Nierle and E.F. Pfeiffer. Dept, of Inter­
nal Medicine, Endocrinology and Metabolism, University of Ulm, 
FRG. Alexander von Humboldt-Fellow 1974/75. Supported by 
Deutsche Forschungsgemeinschaft, SFB 87 Endokrinologie.
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Sustained Insulin Release in Response to 
Intravenous Infusion of Insulin Releasing 
Polypeptide (IRP) in the Rat
Ahmad A. Shabaan, M.Sc.,  Desmond S. Turner, Ph.D.,  and 
Vincent Marks, D.M., Surrey, England
SUMMARY
A greatly elevated and sustained insulinemic response was 
evoked in rats by the intravenous infusion of a solution of IRP in 
glucose compared with that produced by glucose alone. Larger 
doses of IRP produced correspondingly greater increases in insulin 
release.
IRP enhanced glucose disposal up to a finite limit despite higher 
plasma insulin levels suggesting that there is a maximum rate of 
glucose disposal under conditions of intense insulin stimulation. 
Diabetes 23:902-04, November, 1974.
Intestinal insulin releasing polypeptide (IRP), a 
crude extract of porcine intestine of molecular weight 
between 3 ,000-5 ,000  is known to be free from con­
tamination by most of the well recognized gastrointes­
tinal hormones including secretin, cholecystokinin- 
pancreozymin (PZ-CCK) and enteroglucagon.1 The 
possibility of contamination by gastrin inhibitory 
polypeptide (GIP) has been considered,2 but has not 
been resolved.
IRP has been shown to enhance insulin release in 
response to intravenous glucose in the rat3 and the 
baboon.4 It has been suggested that IRP may contain 
the intestinal hormone responsible for the greater in­
sulinemic response to oral as compared to intravenous 
glucose.5 None of the well characterized intestinal 
hormones satisfactorily explains all of the observed 
phenomena.
From the Departm ent of Biochemistry, University of Surrey, 
Guildford, Surrey, England.
Accepted for publication August 16, 1974.
Information on the biological activity of IRP pub­
lished to date has largely been concerned with the 
insulinemic response to its rapid intravenous injec­
tion. However, since the insulin secretory response to 
oral glucose is maintained over relatively prolonged 
periods IRP must be shown, if it is to qualify as the 
intestinal mediator of augmented insulin release, to be 
capable of exerting a sustained effect on insulin release 
when given by constant intravenous infusion. This 
paper describes experiments performed in rats to test 
this proposition.
MATERIALS A N D  M ETHODS
Overnight fasted Wistar rats, aged twelve weeks 
and weighing 300-325 g m ., were anesthetized with 
Nem butal (40 m g. per kg. body w eight) intra- 
peri toneally. IRP, prepared by the method of Turner 
et a l . ,1 was dissolved in glucose solutions (7 per cent 
or 14 per cent w/v) and given by constant intravenous 
infusion into a femoral vein for thirty minutes at a rate 
of 0 .1 ml. per minute.
Controls received glucose infusions without added 
IRP at the same concentrations as the test animals 
(i.e. 25 mg. per kg. body weight per minute, or 50 
mg. per kg. body weight per minute). The detailed 
protocol o f each experiment is given in the Results 
section.
Blood was sampled from the tail vein at frequent 
intervals. Blood glucose was measured using an auto­
mated glucose-oxidase method and plasma insulin by 
a double antibody radioimmunoassay.6
RESULTS
1. Effect of different doses of IRP on plasma insulin and 
blood glucose
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The mean blood glucose and plasma insulin levels 
observed in each of three groups of four rats given 
intravenous infusions of 14 per cent w/v glucose plus 
IRP, or glucose alone for the control group, are shown 
in figure 1.
Plasma glucose levels were not significantly differ­
ent at five or ten minutes after starting the infusion, 
but at twenty minutes rats receiving glucose alone had 
significantly higher (p <  0.05) blood glucose levels 
than those receiving glucose plus IRP. This continued 
for the rest of the experiment. Blood glucose levels in 
the two groups of rats receiving different doses of IRP 
were similar throughout.
W ithin five minutes, and at both (33 and 107 
Mg/kg. per minute) dose levels, IRP caused a signifi­
cant (p <  0 .01) and sustained hyperinsulinemic re­
sponse compared with that produced by glucose alone. 
W ith the larger doses of IRP plasma insulin concen­
Blood glucose responses to infusions of IRP at different dose 
rates during continuous glucose infusion
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FIG. 1. Mean blood glucose levels (±  S.E.M.) in three groups of 
four rats given a thirty minute intravenous infusion of:
1. glucose alone (50 mg. per kg. per minute)
2. glucose (50 mg. per kg. per minute) plus IRP (33 
fxg/kg.  per minute)
3. glucose (50 mg. per kg. per minute) plus IRP (107 
j ig/kg.  per minute)
tration averaged over 2 ,000  gU /m l. and were the 
highest sustained levels ever observed in this labora­
tory. In all cases plasma insulin levels fell precipitously 
at the conclusion of the intravenous infusion and did 
not differ significantly from each other at either forty- 
five or sixty minutes.
These results show that both doses of IRP depressed 
the blood glucose concentration to the same extent 
when compared with the glycemia produced by glu­
cose alone.
2. Effect on plasma insulin and blood glucose of a constant 
dose of IRP with different glucose loads
Figure 2 illustrates mean blood glucose and plasma 
insulin levels in each of four groups of four rats thirty 
minutes after commencing an intravenous infusion of 
glucose (either 25 or 50 mg. per kg. per minute) with 
or without IRP (33 nglkg. per minute). Mean blood 
glucose levels were higher in the rats that received the
Plasma insulin responses to infusions of IRP at different dose 
rates during continuous glucose infusion
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FIG. 1 A.Mean plasma insulin levels (±  S.E.M.) in three groups of 
four rats given a thirty minute intravenous infusion of:
1. glucose alone (50 mg. per kg. per minute)
2. glucose (50 mg. per kg. per minute) plus IRP (33 
/xg/kg. per minute)
3. glucose (50 mg. per kg. per minute) plus IRP (107 
jxg/kg. per minute)
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FIG. 2. Mean (±  S.E.M.) blood glucose (on the left) and plasma 
insulin levels (on the right) in two groups of four rats after 
thirty minutes intravenous infusion containing IRP at con­
stant dosage (33/rg/kg. per minute) and different amounts 
of glucose (25 and 50 mg. per kg. per minute). Two control 
groups, each of four rats, were infused with glucose alone 
at the appropriate rate.
larger glucose load, but in each case were significantly 
lower in the animals that also received IRP. Plasma 
insulin levels were higher in animals receiving the 
larger dose of glucose and the augmentory effect of 
IRP on insulin release was significantly greater (p <  
0 . 01).
DISCUSSION
The experiments described indicate that IRP given 
by constant intravenous infusion is capable, in the 
presence of mild to moderate hyperglycemia, of caus­
ing a marked and sustained augmentation of insulin 
secretion which is of more than sufficient magnitude 
to explain the greater insulin releasing potential of
oral versus intravenous glucose.5 Indeed, the extent of 
the hyperinsulinemia observed with large doses of IRP- 
indicates its enormous insulinotropic potency even 
though the preparation currently available is far from 
pure.
The greater plasma insulin response observed with 
the larger doses of IRP, under these conditions, is 
consistent with the dose response relationship between 
IRP and insulinemia, previously reported.1 Even so 
both doses of IRP had the same effect on glucose 
tolerance judging from the magnitude of the hyper­
glycemic response to the intravenous glucose load and 
the rate of glucose disappearance from the blood (y) at 
the conclusion of the infusion. These observations 
suggest that, in vivo, there is a maximum rate of 
glucose disposal and further increments above a still 
poorly defined plasma insulin concentration have no 
additional effect upon glucose tolerance.
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Summary. Intestinal insulin releasing polypeptide 
(IRP) has been shown to potentiate the release of insulin 
in response to glucose both in  vitro and in  vivo in the rat. 
Adrenaline reduced the insulin secretory response to the 
intravenous infusion (I.Y.) of glucose and to the infusion
of glucose with IRP given either as a rapid injection or 
as constant infusion.
K ey words-. Adrenaline, IRP, intestinal hormones, in­
sulin release, glucose infusion, secretin, glucose tolerance.
The nature of the mediator of intestinal augmenta­
tion of insulin secretion has aroused much speculation 
since the phenomenon was first described by McIntyre 
et al in 1964 [1]. Most of the well-known and charac­
terised intestinal hormones have been proposed at
* The present study incorporates work accepted for 
the award of M.Sc. in Clinical Biochemistry to Ahmad A. 
Shabaan at the University of Surrey.
some time or other but none satisfactorily fulfils the 
role of the intestinal mediator [2, 3]. An intestinal in­
sulin releasing polypeptide [IRP] which contains none 
of these hormones has recently been isolated and par­
tially purified [4, 5]. It has been shown to potentiate 
the release of insulin in response to glucose, both in  
vitro and in vivo, but to have no, or little effect in the 
absence of induced hyperglycaemia [5, 6].
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Fig. 1. Mean blood glucose and plasma insulin levels (± S.E.M.) in two groups of six rats given either an I.V, 
infusion of glucose (50 mg/kg/min) or glucose plus adrenaline (100 ng/kg/min)
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The inhibitory effect of adrenaline and nor-adrena- 
lirie upon pancreatic insulin release provoked by intra­
venous glucose is well recognised [7, 8]. Much less in­
formation is available about their effect upon oral 
glucose mediated insulin secretion. In a brief note 
Langs and Friedberg [9] reported that, in man, the
I. V. infusion of adrenaline at a rate sufficient complete­
ly  to suppress glucose stimulated insulin secretion, did 
not suppress the effect of oral glucose on insulin release.
glucose plus IR P are reported and their possible rele­
vance to the nature of the intestinal mediator discus­
sed.
Materials and Methods
Overnight fasted Wistar rats aged 12 weeks, weigh­
ing 300—325 g, were anaesthetised with Nembutal®
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G lucose a lone ( 50m g/kg /m in  ) ■ -m
G lucose +  Adrenaline ( lO O ng/kg/m in )900400
INSULIN G lucose +  IR P  ( 1 m g/kg  ) 0  O 
G lucose + Adrenaline +  IR P  ®— ®
GLUCOSE
800
350
700
300
600
E
s  250
500b oE
u
§ 200 
O
400
300
® 150
200
150100
100
.IRP IRP
I. V. Infusion I. V. Infusion
20 30
T im e ( M inutes ) T im e  ( M inutes )
Fig. 2.
*»■
Mean blood glucose and plasma insulin levels (i S.E.M.) in four groups of Wistar rats given an intravenous
glucose infusion (50 mg/kg/min) over 30 min
Group No. of Glucose IRP (in saline) Adrenaline
No. Rats (50 mg/kg/min) (1 mg/kg) (100 ng/kg/min)
1 6 + — —
2 6 ' + — +
3 4 + + —
4 . 4 + + +
This was not confirmed [10]. Nelson et al [11] reported 
that adrenaline did not suppress secretin induced in­
sulin release and on this basis suggested that in man 
secretin might be a suitable candidate for the hypo­
thetical alimentary mediator.
In the present paper the results of studies in the 
rat concerning the effect of adrenaline on the insulin 
response to the intravenous infusion of glucose and of
(40 mg/kg body weight, I.P.). IRP, prepared as previ­
ously described [5] was dissolved in saline or, together 
with adrenaline (B.P. MacCarthys), either in 7% or 
14% w/v glucose solution, containing ascorbic acid 
(2 mg/ml) as adrenaline preservative. The constant in­
fusion of approximately 0.1 ml/min for 30 min of the 
glucose or glucose plus adrenaline solutions was given 
into a femoral vein using a syringe pump. The exact
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protocol followed in each experiment is given in the 
results section.
Blood for glucose and plasma insulin measurements 
was obtained at regular intervals from the tail vein. 
Blood glucose was measured on the Autoanalyzer 
(Technicon Ltd) using an automated glucose oxidase 
method (Boehringer). Plasma insulin was determined 
by a double antibody radioimmunoassay procedure 
[12] using human insulin as standard.
The effect of adrenaline on insulin release after a 
rapid injection of IR P dissolved in saline was studied 
15 min after the start of an infusion of either glucose 
or glucose plus adrenaline. The results, shown in Fig. 
2, indicate that insulin release following rapid intra­
venous injection of IR P was markedly, but not com­
pletely, inhibited by adrenaline (p<0.001). The effect 
of adrenaline on insulin release provoked by a conti- 
nous infusion of IR P is shown in Fig. 3. In this experi-
Effect of Adrenaline on In su lin  r e le a s e  in  re s p o n s e  to  IR P  infusion  in  th e  R at
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Fig. 3. Mean blood glucose and plasma insulin levels (i S.E.M.) in three groups of four rats. The first (control) 
group was given an I.V. glucose infusion (25 mg/kg/min) for 30 min and the second was given glucose plus adrena­
line (100 ng/kg/min). The third group received IRP (33 ptg/kg/min) in addition to glucose and adrenaline
Results
Preliminary experiments were carried out to find 
the smallest dose of adrenaline to suppress insulin 
secretion in response to I.V. glucose infusions in the 
rat. These experiments showed that adrenaline in doses 
within the range 10—60 ng/kg/min, which had pre­
viously been reported as effective in man, [8] did not 
cause significant inhibition of insulin release in the rat. 
Adrenaline at a dose level of 100 ng/kg/min inhibited 
insulin release at all time intervals (Fig. 1), despite 
blood glucose levels much higher than in animals re­
ceiving glucose alone. This dose of adrenaline was used 
in all subsequent experiments,
ment glucose was infused at a lower rate than in pre­
vious experiments, which accounts for the lower blood  
glucose levels throughout. The marked and sustained 
elevation of plasma insulin produced by IR P plus glu­
cose, compared with that produced by glucose alone, 
was significantly attenuated, but not abolished, by 
adrenaline at all time intervals during the infusions 
(p <0.001 at 20 min).
Discussion
The dose of adrenaline found in the present study  
to be effective as an inhibitor of insulin secretion in re­
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sponse to intravenous (I.V.) glucose infusions in rats 
was larger than that reported by Cerasi et al. [8] to be 
effective in humans, but similar to that actually used 
in man by most previous investigators [7, 9,10, 12,13].
It is clear from the experiments described that 
adrenaline markedly inhibits the potentiating effect of 
IR P upon glucose-stimulated insulin secretion in the 
rat. Whether this is evidence for or against its merits 
as a candidate for the role of alimentary mediator of 
insulin release is uncertain. In contrast to the plethora 
of studies demonstrating inhibition by catecholamines 
of glucose mediated insulin release in vivo and in vitro, 
both in animals and in man, the only studies of their 
effect upon alimentary mediated insulin release known 
to us are those of Langs and Friedberg [9] and Fallucca 
et al. [10]. The latter showed, in three post-gastrectomy 
patients, a substantial and highly significant, though 
incomplete, inhibition by adrenaline of the exaggerated 
insulinaemie response to oral versus intravenous glu­
cose.
IR P would seem, therefore, to qualify for further 
consideration as an intestinal mediator of glucose sti­
mulated hyperinsulinaemia.
Acknowledgements. Thanks are due to the British Dia­
betic Association and Wellcome Foundation, Beckenham, 
for generous support.
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protocol followed in each experiment is given in the 
results section.
Blood for glucose and plasma insulin measurements 
was obtained at regular intervals from the tail vein. 
Blood glucose was measured on the Autoanalyzer 
(Technicon Ltd) using an automated glucose oxidase 
method (Boehringer). Plasma insulin was determined 
by a double antibody radioimmunoassay procedure 
[12] using human insulin as standard.
The effect of adrenaline on insulin release after a 
rapid injection of IR P dissolved in saline was studied 
15 min after the start of an infusion of either glucose 
or glucose plus adrenaline. The results, shown in Fig. 
2, indicate that insulin release following rapid intra­
venous injection of IR P  was markedly, but not com­
pletely, inhibited by adrenaline (p<0.001). The effect 
of adrenaline on insulin release provoked by a conti- 
nous infusion of IR P is shown in Fig. 3. In this experi-
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Fig. 3. Mean blood glucose and plasma insulin levels (i S.E.M.) in three groups of four rats. The first (control) 
group was given an I.Y. glucose infusion (25 mg/kg/min) for 30 min and the second was given glucose plus adrena­
line (100 ng/kg/min). The third group received IRP (33 gg/kg/min) in addition to glucose and adrenaline
Results
Preliminary experiments were carried out to find 
the smallest dose of adrenaline to suppress insulin 
secretion in response to I.V. glucose infusions in the 
rat. These experiments showed that adrenaline in doses 
within the range 10—60 ng/kg/min, which had pre­
viously been reported as effective in man, [8] did not 
cause significant inhibition of insulin release in the rat. 
Adrenaline at a dose level of 100 ng/kg/min inhibited 
insulin release at all time intervals (Fig. 1), despite 
blood glucose levels much higher than in animals re­
ceiving glucose alone. This dose of adrenaline was used 
in all subsequent experiments,
ment glucose was infused at a lower rate than in pre­
vious experiments, which accounts for the lower blood  
glucose levels throughout. The marked and sustained  
elevation of plasma insulin produced by IR P plus glu­
cose, compared with that produced by glucose alone, 
was significantly attenuated, but not abolished, by  
adrenaline at all time intervals during the infusions 
(p<0.001 at 20 min).
Discussion
The dose of adrenaline found in the present study  
to be effective as an inhibitor of insulin secretion in re­
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sponse to intravenous (I.V.) glucose infusions in rats 
was larger than that reported by Cerasi et al. [8] to be 
effective in humans, but similar to that actually used 
in man by most previous investigators [7, 9,10, 12, 13].
It is clear from the experiments described that 
adrenaline markedly inhibits the potentiating effect of 
IR P upon glucose-stimulated insulin secretion in the 
rat. Whether this is evidence for or against its merits 
as a candidate for the role of alimentary mediator of 
insulin release is uncertain. In contrast to the plethora 
of studies demonstrating inhibition by catecholamines 
of glucose mediated insulin release in vivo and in vitro, 
both in animals and in man, the only studies of their 
effect upon alimentary mediated insulin release known 
to us are those of Langs and Friedberg [9] and Fallucca 
et al. [10]. The latter showed, in three post-gastrectomy 
patients, a substantial and highly significant, though 
incomplete, inhibition by adrenaline of the exaggerated 
insulinaemic response to oral versus intravenous glu­
cose.
IR P would seem, therefore, to qualify for further 
consideration as an intestinal mediator of glucose sti­
mulated hyperinsulinaemia.
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